BioNxt Solutions Inc. (CVE:BNXT)

BRIEF

published on 11/20/2025 at 09:10, 5 months 10 days ago

BioNxt Receives Eurasian Patent for Sublingual Cladribine Platform

Global Market Autoimmune Diseases Patent Grant BioNxt Solutions Sublingual Cladribine
PRESS RELEASE

published on 11/20/2025 at 09:05, 5 months 10 days ago

BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
BioNxt Solutions Inc. receives Eurasian Patent No. 051510 for sublingual anticancer drug delivery system, a key milestone in global IP strategy. Expansion to EU and US markets in progress

BioNxt Solutions Inc. Sublingual Delivery Eurasian Patent Pharmaceutical Markets Global IP Strategy
BRIEF

published on 11/04/2025 at 09:10, 5 months 26 days ago

BioNxt Receives European Patent Notification for Cladribine Thin-Film

Multiple Sclerosis Oral Therapies Cladribine European Patent BioNxt
PRESS RELEASE

published on 11/04/2025 at 09:05, 5 months 26 days ago

BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
BioNxt Solutions Inc. receives 'Intention to Grant' notification from European Patent Office for sublingual cladribine thin-film formulation for MS treatment, securing extensive IP protection across Europe and Eurasia

BioNxt Solutions Inc. European Patent Office MS Treatment Sublingual Thin-Film Global Patent Coverage
BRIEF

published on 10/30/2025 at 08:10, 6 months ago

BioNxt Solutions Inc. Advances Patent for Cancer Drug Delivery

Multiple Sclerosis Drug Delivery BioNxt Solutions Eurasian Patent Patent Strategy
PRESS RELEASE

published on 10/30/2025 at 08:05, 6 months ago

BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
BioNxt Solutions Inc. receives "Readiness to Grant" notification from EAPO for comprehensive patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases, including lead product BNT23001 for MS treatment. Patent protection strengthens commercialization strategy

BioNxt Solutions Inc. Patent Application Sublingual Drug Delivery Anticancer Drugs EAPO
BRIEF

published on 10/21/2025 at 09:10, 6 months 9 days ago

BioNxt Initiates Sublingual Cladribine Study for MS Treatment Optimization

Multiple Sclerosis Bioavailability Drug Delivery Bioequivalence Study Sublingual Cladribine
PRESS RELEASE

published on 10/21/2025 at 09:05, 6 months 9 days ago

BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
BioNxt Solutions Inc. announces a large-mass animal bioequivalence study for sublingual Cladribine formulation, targeting multiple sclerosis treatment, to optimize dosage parameters for upcoming human study

BioNxt Solutions Inc. Multiple Sclerosis Treatment Bioequivalence Study Drug Delivery Technologies Sublingual Cladribine Formulation
BRIEF

published on 10/10/2025 at 01:55, 6 months 20 days ago

BioNxt Solutions Addresses AGM Voting Amid Postal Strike

AGM Voting Marketing Campaign Canada Post Strike Proxy Submission
PRESS RELEASE

published on 10/10/2025 at 01:50, 6 months 20 days ago

BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities
BioNxt Solutions Inc. provides alternative voting options for shareholders due to Canada Post mail strike. Annual general meeting details and proxy voting instructions shared

Annual General Meeting Shareholders BioNxt Solutions Inc. Proxy Voting Voting Options

Published on 04/30/2026 at 15:10, 28 minutes ago

Formation Metals Announces Non-Brokered Offering of up to $15 Million Fully Allocated
Published on 04/30/2026 at 15:00, 38 minutes ago

Wi2Wi Corporation Announces Grant of Options
Published on 04/30/2026 at 15:00, 38 minutes ago

Karbon-X Advances Sur del Meta REDD+ Project with Biodiversity Partnership
Published on 04/30/2026 at 15:00, 38 minutes ago

Datavault AI and Kings Mine Capital Agree to Establish $150 Million+ GoldVault(TM) Tokenization Program
Published on 04/30/2026 at 14:57, 41 minutes ago

Cotec Holdings Corp. Files Annual Audited Financial Statements and MD&A

View all ACCESSWIRE

Published on 04/30/2026 at 15:21, 16 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 04/30/2026 at 15:21, 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 04/30/2026 at 15:20, 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/30/2026 at 15:20, 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited
Published on 04/30/2026 at 15:19, 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: NCC Group plc

View all EQS

Published on 04/30/2026 at 07:45, 7 hours 53 minutes ago

The Belgian State and ENGIE Group enter into exclusive negotiations for the acquisition by Belgium of ENGIE's nuclear activities
Published on 04/30/2026 at 07:30, 8 hours 8 minutes ago

New Gimv Anchor investment: acquisition of 5% shareholding in Azelis
Published on 04/30/2026 at 07:29, 8 hours 9 minutes ago

First Quarter Revenues 2026
Published on 04/29/2026 at 23:00, 16 hours 38 minutes ago

INFORMATION ON ANNUAL FINANCIAL STATEMENTS
Published on 04/29/2026 at 18:31, 21 hours 6 minutes ago

FIRST QUARTER 2026 TURNOVER

View all LES ECHOS COMFI WIRE

News